Veda N. Giri, MD

Veda N. Giri, MD

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania

Veda N. Giri, MD, is an Associate Professor in Medical Oncology and Cancer Biology at the Sidney Kimmel Cancer Center at Thomas Jefferson University in Philadelphia. She is a medical oncologist with a clinical and research interest in inherited cancer risk assessment. Dr. Giri is also the Director of Cancer Risk Assessment and Clinical Cancer Genetics at Thomas Jefferson University. Her clinical efforts are focused on the genetic evaluation of inherited risk for GU cancers, specifically prostate, kidney, and upper tract urothelial cancers. Her research studies encompass genetic characterization of cancer risk using sequencing technologies, molecular signatures, and novel biomarkers to ultimately reduce cancer-related morbidity and mortality. Her research also has a strong focus in cancer disparities. Dr. Giri received her medical degree from Jefferson Medical College, and proceeded to complete her Residency in Internal Medicine and Fellowship in Hematology-Oncology at the University of Michigan. She then completed advanced training in molecular cancer genetics at Fox Chase Cancer Center (FCCC). From 2006-2014, she directed prostate cancer risk assessment at FCCC, developing studies focused on evaluating the role of genetic markers in prostate cancer risk assessment. Dr. Giri has served on several national committees, including the National Comprehensive Cancer Network Prostate Cancer Early Detection Panel and NIH PDQ® Cancer Genetics Editorial Board, contributing expertise in cancer risk assessment and prostate cancer genetics.

Disclosures:

Articles by Veda N. Giri, MD

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019

Veda N. Giri, MD, Director of Cancer Risk Assessment and Clinical Cancer Genetics at the Sidney Kimmel Cancer Center of Thomas Jefferson University, discusses the decisions reached about the implementation of germline testing at the 2019 Philadelphia Prostate Cancer Consensus Conference. She summarizes the conclusions the voting participants came to, including recommendations on who should receive germline testing, what should be discussed with men in terms of informed consent, which genes should be prioritized for testing, and who should be enrolled in precision medicine trials, among other topics. In a follow-up interview, E. David Crawford, MD, Professor of Urology at the University of California, San Diego, asks Dr. Giri about which laboratories and panels to use, the limitations of commercial genetic testing like 23andMe, and the role of online genetic counseling.

Read More

Join the GRU Community

- Why Join? -